{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:43:16Z","timestamp":1789879396212,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T00:00:00Z","timestamp":1380844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.vaccine.2013.09.032","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T03:30:17Z","timestamp":1380598217000},"page":"5745-5753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study"],"prefix":"10.1016","volume":"31","author":[{"given":"Lynette","family":"Denny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chivaugn","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Hezareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Dobbelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.09.032_bib0005","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","article-title":"Worldwide burden of cervical cancer in 2008","volume":"22","author":"Arbyn","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0020","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnci\/91.3.226","article-title":"Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women","volume":"91","author":"Palefsky","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0030","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/AOG.0b013e3181743327","article-title":"Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women","volume":"111","author":"Denny","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/1471-2458-8-262","article-title":"Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening","volume":"8","author":"Kahesa","year":"2008","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0040","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1086\/599123","article-title":"Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women","volume":"199","author":"Singh","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2334-10-242","article-title":"Assessing the relationship between HIV infection and cervical cancer in Cote d\u2019Ivoire: a case\u2013control study","volume":"10","author":"Adjorlolo-Johnson","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/QAI.0b013e3181b327e7","article-title":"Association of oncogenic and nononcogenic human papillomavirus with HIV incidence","volume":"53","author":"Auvert","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0055","unstructured":"UNAIDS Report on the Global AIDS Epidemic 2010. http:\/\/www.unaids.org\/globalreport\/Global_report.htm [accessed 11.7.12]."},{"key":"10.1016\/j.vaccine.2013.09.032_bib0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2407-6-135","article-title":"HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case\u2013control study","volume":"6","author":"Moodley","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0065","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0070","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0075","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0085","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"GlaxoSmithKline Vaccine HPV-007 Study Group","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0100","unstructured":"WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization, 2007."},{"key":"10.1016\/j.vaccine.2013.09.032_bib0105","unstructured":"Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. World Health Organization, 2006."},{"key":"10.1016\/j.vaccine.2013.09.032_bib0110","unstructured":"Provincial Administration Western Cape. Antiretroviral Treatment Protocol. Version 2, April 2004."},{"key":"10.1016\/j.vaccine.2013.09.032_bib0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/hv.4.6.6912","article-title":"Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine","volume":"4","author":"Dessy","year":"2008","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0120","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12\u201324 in a Phase III randomized study of healthy women aged 18\u201345 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials","volume":"5","author":"Descamps","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0130","first-page":"157","article-title":"Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions","volume":"11","author":"van den Berg","year":"2009","journal-title":"AIDS Rev"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0135","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-1-4615-1823-5_21","article-title":"Monophosphoryl lipid A as an adjuvant, Past experiences and new directions","volume":"6","author":"Ulrich","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14760584.2.2.219","article-title":"Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529","volume":"2","author":"Evans","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.09.032_bib0150","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B-cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminum salt combination (AS04) compared to aluminum salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T09:53:19Z","timestamp":1539337999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13012735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":30,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0264410X13012735"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}